Twist Bioscience Co. to Post Q1 2023 Earnings of ($1.06) Per Share, William Blair Forecasts (NASDAQ:TWST)

Twist Bioscience Co. (NASDAQ:TWSTGet Rating) – William Blair increased their Q1 2023 earnings estimates for shares of Twist Bioscience in a research report issued on Monday, November 21st. William Blair analyst M. Larew now expects that the company will earn ($1.06) per share for the quarter, up from their prior forecast of ($1.25). The consensus estimate for Twist Bioscience’s current full-year earnings is ($4.52) per share. William Blair also issued estimates for Twist Bioscience’s Q2 2023 earnings at ($1.08) EPS, Q3 2023 earnings at ($1.16) EPS, Q4 2023 earnings at ($1.17) EPS and FY2023 earnings at ($4.47) EPS.

A number of other research firms have also weighed in on TWST. Robert W. Baird reduced their target price on shares of Twist Bioscience from $56.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday. SVB Leerink reduced their target price on shares of Twist Bioscience from $45.00 to $30.00 and set a “market perform” rating on the stock in a report on Monday. Finally, Barclays reduced their target price on shares of Twist Bioscience from $45.00 to $43.00 and set an “overweight” rating on the stock in a report on Monday.

Twist Bioscience Price Performance

TWST opened at $25.53 on Wednesday. Twist Bioscience has a fifty-two week low of $23.90 and a fifty-two week high of $99.74. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -6.33 and a beta of 1.15. The company’s 50 day moving average price is $32.37 and its two-hundred day moving average price is $36.79.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently modified their holdings of the company. Captrust Financial Advisors boosted its stake in shares of Twist Bioscience by 101.3% in the 2nd quarter. Captrust Financial Advisors now owns 759 shares of the company’s stock valued at $27,000 after purchasing an additional 382 shares during the last quarter. Advanced Research Investment Solutions LLC bought a new stake in shares of Twist Bioscience in the 1st quarter valued at $35,000. National Bank of Canada FI boosted its stake in shares of Twist Bioscience by 3,333.3% in the 2nd quarter. National Bank of Canada FI now owns 1,030 shares of the company’s stock valued at $36,000 after purchasing an additional 1,000 shares during the last quarter. CWM LLC boosted its stake in Twist Bioscience by 430.7% during the second quarter. CWM LLC now owns 1,226 shares of the company’s stock worth $43,000 after acquiring an additional 995 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in Twist Bioscience by 155.6% during the first quarter. Canada Pension Plan Investment Board now owns 1,066 shares of the company’s stock worth $52,000 after acquiring an additional 649 shares in the last quarter.

Insider Activity

In other news, SVP Paula Green sold 8,514 shares of the company’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $37.43, for a total value of $318,679.02. Following the sale, the senior vice president now directly owns 14,199 shares of the company’s stock, valued at approximately $531,468.57. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last three months, insiders have sold 9,211 shares of company stock valued at $341,371. 3.10% of the stock is currently owned by insiders.

About Twist Bioscience

(Get Rating)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Stories

Earnings History and Estimates for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.